Plant where Biocon and Mylan will produce their Lantus copy spanked with FDA Form 483

Biocon and Mylan have won approval in Europe for their substitute of Sanofi’s megablockbuster Lantus and hope to get an FDA nod as well. But the two have hit another manufacturing snag on their march toward an FDA nod.Original Article